(:CNCE)

Feb 15, 2023 07:00 am ET
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibitor, is being developed for the treatment
Feb 13, 2023 10:16 am ET
CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) to Sun Pharmaceutical Industries Limited is fair to Concert shareholders. Per the terms of the agreement, Sun Pharma would acquire Concert for an upfront payment of $8.00 per share in cash, plus a non-tradeable contingent value right entitling Concert shareholders to receive up to an additional $3.50 per share in cash, payable upon deuruxolitinib achieving certain net sales milestones within specified periods.
Feb 07, 2023 12:17 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNCE, AQUA, LPTX, ALR
NEW YORK, Feb. 7, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 31, 2023 09:45 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALBO, CNCE, AQUA, LPTX
NEW YORK, Jan. 31, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 30, 2023 11:53 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANGN, CNCE, AQUA
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Angion Biomedica Corp. (NASDAQ:...
Jan 29, 2023 11:38 pm ET
Moore Kuehn Encourages KERN, CNCE, AQUA and ANGN Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek...
Jan 26, 2023 12:12 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZN, ANGN, CNCE
NEW YORK, Jan. 26, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 25, 2023 04:00 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – HZNP, ANGN, TIG, CNCE
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jan 22, 2023 09:46 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNCE, VLTA, GMGI
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Concert Pharmaceuticals, Inc. (NASDAQ:...
Jan 21, 2023 10:46 pm ET
Moore Kuehn Encourages NVCN, VLTA, CNCE, and ANGN Investors to Contact Law Firm
NEW YORK, Jan. 21, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:
Jan 20, 2023 08:00 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – ANGN, CNCE, VLON
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jan 20, 2023 12:04 pm ET
CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Concert Pharmaceuticals, Inc. (NasdaqGM: CNCE) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Concert will receive $8.00 in cash plus one contingent value right (CVR) (entitling its holder to receive up to an additional $3.50 per share of common stock in cash upon achieving certain net sales milestones) for each share of Concert that they own. KSF is seeking to determine whether this con
Jan 19, 2023 05:32 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Concert Pharmaceuticals, Inc.
NEW YORK, Jan. 19, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Concert Pharmaceuticals, Inc. ("Concert" or the "Company") (NASDAQ: CNCE), in connection with the proposed acquisition of the Company by Sun Pharmaceutical Industries Limited via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $8.00 in cash for each share of Concert common stock owned, plus one non-tradeable contingent value right ("CVR") per share. Each CVR will entitle its holder to def
Jan 19, 2023 10:35 am ET
Shareholder Alert: Ademi LLP investigates whether Concert Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Sun Pharma
MILWAUKEE, Jan. 19, 2023 /PRNewswire/ -- Ademi LLP is investigating Concert (NASDAQ: CNCE) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma. 
Jan 19, 2023 10:13 am ET
CNCE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) to Sun Pharmaceutical Industries Limited is fair to Concert shareholders. Per the terms of the agreement, Sun Pharma would acquire Concert for an upfront payment of $8.00 per share in cash, plus a non-tradeable contingent value right entitling Concert shareholders to receive up to an additional $3.50 per share in cash, payable upon deuruxolitinib achieving certain net sales milestones within specified periods.
Jan 19, 2023 09:57 am ET
Thinking about buying stock in Concert Pharmaceuticals, Transocean, Faraday Future Intelligent Electric, Marathon Digital, or Affirm?
NEW YORK, Jan. 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNCE, RIG, FFIE, MARA, and AFRM.
Jan 19, 2023 08:00 am ET
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, “Sun Pharma”)) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (“Concert”) today announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value. Concert stockholders will also receive a non-tradeable contingent value right (CVR) entitling holders t
Nov 21, 2022 07:00 am ET
Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the presentation of data from its THRIVE-AA1 Phase 3 clinical trial during the 12th World Congress for Hair Research. The presentation highlights THRIVE-AA1 study results evaluating Concert’s investigational oral medicine deuruxolitinib (CTP-543) in adult patient
Nov 09, 2022 07:00 am ET
Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT.
Nov 07, 2022 07:00 am ET
Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2022.
Oct 31, 2022 07:00 am ET
Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its third quarter 2022 financial results and provi
Sep 10, 2022 05:30 am ET
Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the presentation of data from its Phase 3 clinical trial, THRIVE-AA1. The presentation highlights THRIVE-AA1 study results evaluating Concert’s oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata, an autoimmune disorder that resul
Sep 06, 2022 07:00 am ET
Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022.
Sep 01, 2022 07:00 am ET
Bridges and Landmarks Across the USA Will Illuminate Blue Throughout the Month of September for Alopecia Areata
In recognition of Alopecia Areata Awareness Month, bridges, buildings and other landmarks across the United States will be illuminated blue to raise awareness for this serious autoimmune disease.
Aug 22, 2022 07:05 am ET
Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that results from the first Phase 3 clinical trial of CTP-543 (THRIVE-AA1) in adult patients with moderate to severe alopecia areata will be presented as a late breaking oral presentation at the 31st European Academy of Dermatology and Venereology (EADV) Congress
Aug 22, 2022 07:00 am ET
Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that BVF Partners L.P. and RA Capital Management have exercised their remaining tranche 1 warrants issued in connection with the Company’s November 2021 financing, resulting in proceeds of $20.9 million to the Company. Concert has the potential to receive an additional $
Aug 04, 2022 07:00 am ET
Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2022.
Aug 01, 2022 07:00 am ET
Concert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced positive topline results from its second Phase 3 clinical trial, THRIVE-AA2, evaluating its oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss. The pr
Jul 29, 2022 07:00 am ET
Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its second quarter 2022 financial results and pro
Jun 14, 2022 09:31 am ET
Thinking about buying stock in Sonim Technologies, Li Auto, Enovix, Concert Pharmaceuticals, or Lineage Cell Therapeutics?
NEW YORK, June 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SONM, LI, ENVX, CNCE, and LCTX.
Jun 09, 2022 07:00 am ET
Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at The JMP Securities Life Sciences Conference on June 16, 2022 at 1:00 p.m. ET in New York, NY.
Jun 07, 2022 07:00 am ET
Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the publication of safety and efficacy data from the randomized, double-blind, placebo-controlled dose-ranging Phase 2 clinical trial for CTP‑543 in the Journal of the American Academy of Dermatology (JAAD). CTP-543 is an investigational oral Janus Kinase (JAK) inhib
Jun 06, 2022 04:01 pm ET
Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of its previously announced underwritten public offering of 10,000,000 shares of its common stock to the public at $4.75 per share. The aggregate gross proceeds to Concert from this offering were $47.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Concert. Concert also announced the receipt of $18.9 million upon the exercise of tranche 1 warrants to purchase 3,981 shares of Series X1 Preferred Stock issued to BVF Partners L.P. and RA Capital Management in November
Jun 01, 2022 07:55 pm ET
Concert Pharmaceuticals Announces Pricing of Public Offering
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $4.75 per share. The gross proceeds to Concert, before deducting underwriting discounts and commissions and estimated offering expenses payable by Concert, are expected to be approximately $47.5 million. Concert has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
May 31, 2022 04:01 pm ET
Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it intends to offer and sell 10,000,000 shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Concert. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
May 27, 2022 09:31 am ET
Thinking about buying stock in Concert Pharmaceuticals, PMV Pharmaceuticals, Allbirds, SIGA Technologies, or Elevation Oncology?
NEW YORK, May 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNCE, PMVP, BIRD, SIGA, and ELEV.
May 26, 2022 09:31 am ET
Thinking about buying stock in Geovax Labs, Concert Pharmaceuticals, Redbox Entertainment, Blacksky Technology, or Big Lots?
NEW YORK, May 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOVX, CNCE, RDBX, BKSY, and BIG.
May 23, 2022 07:00 am ET
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced positive topline results from its recently completed Phase 3 clinical trial, THRIVE-AA1, evaluating its oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair los
May 05, 2022 07:00 am ET
Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2022.
Apr 28, 2022 07:00 am ET
Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the first quarter of 2022, on Thursday, May 5, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its first quarter 2022 financial results and provide
Mar 03, 2022 06:00 am ET
Concert Pharmaceuticals Reports 2021 Financial Results and Provides Company Update
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2021.
Feb 24, 2022 07:00 am ET
Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the fourth quarter of 2021, on Thursday, March 3, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its fourth quarter 2021 financial results and prov
Jan 04, 2022 07:00 am ET
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment in THRIVE-AA2, the second Phase 3 clinical trial to evaluate the efficacy and safety of CTP‑543, an oral Janus kinase (JAK) inhibitor, in adult patients with moderate to severe alopecia areata.
Jan 03, 2022 07:00 am ET
Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. The on-demand presentation will be available beginning at 7:00 a.m. ET on January 10, 2022.
Nov 11, 2021 07:00 am ET
Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a virtual fireside chat at The Jefferies London Healthcare Conference. The on-demand fireside chat will be available beginning at 8:00 a.m. GMT on November 18, 2021.
Nov 09, 2021 07:00 am ET
Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2021.
Nov 04, 2021 09:31 am ET
Thinking about buying stock in Evaxion Biotech, Stratasys, Maxar Technologies, Concert Pharmaceuticals, or Gogo?
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EVAX, SSYS, MAXR, CNCE, and GOGO.
Nov 04, 2021 07:00 am ET
Concert Pharmaceuticals Announces $65 Million Financing
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into an agreement with BVF Partners L.P. (BVF) and RA Capital Management (RA) to raise gross proceeds of $65 million. In addition, Concert will have the potential to receive an additional $103 million upon the full exercise of warrants being issued in connection with the agreement. Closing of the financing is expected on or about November 5, 2021. With the $65 million raised in this financing, Concert now expects to be able to fund its operations into the fourth quarter of 2022. If the warrants being issued in con
Nov 02, 2021 07:00 am ET
Concert Pharmaceuticals to Report Third Quarter 2021 Results on November 9, 2021
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2021, on Tuesday, November 9, 2021, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its third quarter 2021 financial results and prov
Oct 25, 2021 07:00 am ET
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment in THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP‑543, an oral Janus kinase (JAK) inhibitor, in adult patients with moderate to severe alopecia areata. Topline data from THRIVE-AA1 is expected
Sep 03, 2021 07:00 am ET
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate virtually at the following upcoming investor conferences:
Aug 31, 2021 07:00 am ET
Landmarks and Bridges Will Illuminate Blue Throughout the Month of September for Alopecia Areata Awareness Month
In recognition of Alopecia Areata Awareness Month, bridges, buildings and other landmarks across the United States will be illuminated blue to raise awareness for this important autoimmune disease.
Aug 05, 2021 07:00 am ET
Concert Pharmaceuticals Reports Second Quarter 2021 Financial Results
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2021.
Jul 29, 2021 07:00 am ET
Concert Pharmaceuticals to Report Second Quarter 2021 Results on August 5, 2021
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2021, on Thursday, August 5, 2021, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its second quarter 2021 financial results and pro
Jul 01, 2021 07:00 am ET
Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today will present an update from its ongoing open label, long-term extension study of the investigational medicine CTP-543 in patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. The data show that, relative to previous Pha
May 27, 2021 07:00 am ET
Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA2, the second planned Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata. The Company expects to report topline results from THRIVE-AA2 in
May 26, 2021 07:00 am ET
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming virtual investor conferences:
May 17, 2021 04:01 pm ET
Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32 Million
“This transaction provided an opportunity to secure non-dilutive capital and strengthens our balance sheet as we continue to advance CTP-543, our lead asset for alopecia areata, through its Phase 3 program,” stated Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “By receiving these proceeds, we now expect our cash, cash equivalents and investments to fund the Company into the second quarter of 2022.”
May 04, 2021 07:00 am ET
Concert Pharmaceuticals Reports First Quarter 2021 Financial Results
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2021.
Apr 27, 2021 07:00 am ET
Concert Pharmaceuticals to Report First Quarter 2021 Results on May 4, 2021
A live webcast of the conference call may be accessed in the Investors section of the Company’s website at
Mar 02, 2021 07:00 am ET
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming virtual investor conferences:
Feb 25, 2021 07:00 am ET
Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2020, and provided an update on its product pipeline.
Feb 18, 2021 07:00 am ET
Concert Pharmaceuticals to Report Full Year 2020 Results on February 25, 2021
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2020, on Thursday, February 25, 2021, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss 2020 financial results and provide a bus
Feb 01, 2021 07:00 am ET
Concert Pharmaceuticals Announces Results from CTP-692 Phase 2 Trial in Patients with Schizophrenia
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that its Phase 2 clinical trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did not meet the primary endpoint or other secondary endpoints. CTP-692 is a deuterated form of D-serine, an endogenous amino acid that is a co-agonist of the NMD
Nov 09, 2020 07:00 am ET
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences:
Nov 05, 2020 06:00 am ET
Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2020.
Nov 03, 2020 07:00 am ET
Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata. The Company expects to report topline results from THRIVE-AA1 in 2022. A
Oct 29, 2020 10:00 am ET
Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented initial data from the ongoing long-term, open-label extension study of the investigational medicine CTP-543 in patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. The data from this long-term extension study
Oct 29, 2020 07:00 am ET
Concert Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss third quarter financial results and provide a business updat
Oct 22, 2020 07:00 am ET
Concert Pharmaceuticals Announces Publication on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Journal of Investigative Dermatology published results from a survey designed to understand the burden and everyday experience for patients living with moderate-to-severe alopecia areata. The survey was conducted by the National Alopecia Areata Foundation (N
Oct 13, 2020 07:00 am ET
Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The meeting will be held virtually October 29-31, 2020. The
Sep 29, 2020 07:00 am ET
Concert Pharmaceuticals Completes Enrollment in CTP-692 Phase 2 Trial in Patients with Schizophrenia
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of its Phase 2 clinical trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia. Topline data from the trial are expected in the first quarter of 2021.
Sep 08, 2020 07:00 am ET
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming virtual investor conferences:
Aug 18, 2020 06:00 am ET
Concert Pharmaceuticals to Present at The JMP Securities CNS Forum
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that James V. Cassella, Ph.D., Chief Development Officer, will be participating virtually in a fireside chat at The JMP Securities CNS Forum on August 19, 2020, at 10:00 a.m. ET. A live webcast of the event may be accessed in the
Aug 06, 2020 07:00 am ET
Concert Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Company Update
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2020.
Jul 30, 2020 07:00 am ET
Concert Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 6, 2020
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss second quarter financial results and provide a business updat
Jun 12, 2020 04:01 pm ET
Concert Pharmaceuticals Releases Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today released new data analyses from its Phase 2 dose-ranging clinical trial of its investigational agent CTP‑543 for the treatment of moderate-to-severe alopecia areata. The results were selected as an oral presentation at the Late-Breaking Research Program at the American Academy of
May 26, 2020 07:00 am ET
Concert Pharmaceuticals to Webcast Fireside Chat at Jefferies Virtual Global Healthcare Conference
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that Roger Tung, Ph.D., President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Virtual Global Healthcare Conference on June 2, 2020, at 2:00 p.m. ET.
May 12, 2020 07:00 am ET
Concert Pharmaceuticals to Webcast Presentation at UBS Virtual Healthcare Conference
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the 2020 UBS Virtual Global Healthcare Conference on May 19, 2020 at 3:00 p.m. ET.
Apr 30, 2020 07:00 am ET
Concert Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Update on Clinical Programs
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2020.
Apr 23, 2020 07:00 am ET
Concert Pharmaceuticals to Report First Quarter 2020 Financial Results on April 30, 2020
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2020 financial results on Thursday, April 30, 2020, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss first quarter financial results and provide a business update.
Apr 01, 2020 07:00 am ET
Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the details of its pivotal Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. Concert discussed key aspects of its planned Phase 3 trials in adult patients with the U.S. Food
Feb 27, 2020 07:00 am ET
Concert Pharmaceuticals Reports 2019 Financial Results and Provides Update on Clinical Programs
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the year ended December 31, 2019 and provided an update on its product pipeline and corporate activities.
Feb 24, 2020 07:00 am ET
Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at the 2020 American Academy of Dermatology Annual Meeting
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that results from its CTP-543 Phase 2 dose-ranging trial in alopecia areata have been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 20-24, 2020, in Denver, CO.
Feb 20, 2020 07:00 am ET
Concert Pharmaceuticals to Report Full Year 2019 Results on February 27, 2020
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2019, on Thursday, February 27, 2020, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss 2019 financial results and provide a bus
Jan 30, 2020 04:01 pm ET
Concert Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of its previously announced underwritten public offering of 5,735,283 shares of its common stock to the public at $9.92 per share, which included the full exercise of the underwriters’ option to purchase 982,863 additional shares of common stock. In addition, and in lieu of common stock, Concert sold to a certain existing investor pre-funded warrants to purchase up to an aggregate of 1,800,000 shares of common stock at a purchase price of $9.919 per pre-funded warrant, which represents the per share public offering price
Jan 28, 2020 09:00 am ET
Concert Pharmaceuticals Announces Pricing of Public Offering
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the pricing of an underwritten public offering of 4,752,420 shares of its common stock at a public offering price of $9.92 per share. In addition, and in lieu of common stock, Concert is offering to a certain existing investor pre-funded warrants to purchase up to an aggregate of 1,800,000 shares of common stock at a purchase price of $9.919 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to Conce
Jan 27, 2020 04:02 pm ET
Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Concert. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Jan 27, 2020 04:01 pm ET
Concert Pharmaceuticals Announces Federal Circuit Granted its Motion to Vacate and Remand PTAB Decision Involving CTP-543
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) granted the Company’s motion to vacate and remand the Patent Trial and Appeal Board (PTAB) decision to invalidate U.S. Patent No. 9,249,149 (’149 patent). Concert’s motion was made in light of the recent CAFC
Jan 22, 2020 08:40 am ET
Concert Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No. 16/098,338 related to CTP-543, the Company’s investigational treatment for alopecia areata. The patent, which is expected to expire in 2037, covers pharmaceutical compositions of CTP-543 and methods of treating alopecia areata with CTP-543. The Company intends to conduct an end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and advance CTP-543 into Phase 3 evaluation in 2020.
Dec 19, 2019 04:05 pm ET
Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed its open label trial evaluating 8 mg twice-daily compared to 16 mg once-daily dosing of CTP-543 in patients with moderate-to-severe alopecia areata. Results in the 8 mg twice-daily arm were consistent with the previously-reported 8 mg twice-daily resul
Dec 02, 2019 07:00 am ET
Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of a Phase 2 clinical trial evaluating CTP-692 as an adjunctive treatment for schizophrenia. CTP-692 is a deuterated form of D-serine, an endogenous amino acid that is a co-agonist of the NMDA receptor. NMDA is believed to play a key role in schizophrenia.
Nov 12, 2019 07:00 am ET
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences:
Nov 07, 2019 07:00 am ET
Concert Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Company Update
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2019.
Nov 06, 2019 07:00 am ET
Concert Pharmaceuticals to Host KOL Webcast Event Focused on CTP-692 and Schizophrenia
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will host a conference call and webcast event with a key opinion leader in the field of psychiatry and schizophrenia on Thursday, November 14, 2019. The event will highlight CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schi
Oct 31, 2019 07:00 am ET
Concert Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 7, 2019
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2019 financial results on Thursday, November 7, 2019, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss third quarter financial results and provide a business update. Individuals
Oct 12, 2019 03:15 am ET
Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented results from its recently completed Phase 2 dose-ranging trial of the investigational medicine CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. Patients in the study treated with either 8 mg twice-daily or 12
Oct 02, 2019 07:00 am ET
Concert Pharmaceuticals to Provide Overview of Clinical Pipeline at Cantor Healthcare Conference
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will be providing an overview of the Company’s clinical pipeline following recent updates on the AVP-786 partnered program in a presentation at the Cantor Healthcare Conference on Thursday, October 3, 2019 at 5:20 p.m. ET in New York, NY.
Sep 23, 2019 07:00 am ET
Concert Pharmaceuticals Names Jeffrey Munsie as Chief Legal Officer
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has named Jeffrey A. Munsie to the position of Chief Legal Officer. In this role, Mr. Munsie will have overall responsibility for key general corporate legal functions, including the Company’s public reporting requirements, governance and intellectual property matters, and will se
Sep 17, 2019 07:00 am ET
Concert Pharmaceuticals Completes Enrollment in Second Open Label Trial of CTP-543 to Evaluate Once-Daily vs. Twice-Daily Dosing in Patients with Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in patients with alopecia areata. Topline data from this dose regimen trial is expected in the first half of 2020.
Sep 12, 2019 07:00 am ET
Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present results from its recently completed Phase 2 trial of CTP-543 in patients with moderate-to-severe alopecia areata. These data will be presented in the late breaking news session at the European Academy of Dermatology and Venereology (EADV) Annual Congress to be held
Sep 03, 2019 07:00 am ET
Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced final topline results from its recently completed dose-ranging Phase 2 trial evaluating its investigational medicine CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. Patients treated with either 8 mg twice-da
Aug 29, 2019 07:00 am ET
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences:
Aug 01, 2019 07:00 am ET
Concert Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Company Update
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2019.
Jul 25, 2019 07:00 am ET
Concert Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 1, 2019
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2019 financial results on Thursday, August 1, 2019, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss second quarter financial results and provide a business update. Individuals
Jun 12, 2019 07:00 am ET
Concert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported positive results from two studies in its Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. The safety assessments in the single- and multiple-ascending dose t
Jun 05, 2019 07:00 am ET
Concert Pharmaceuticals Completes Enrollment in Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. The trial is designed to inform on the optimal dosing regimen for CTP-543 f
May 16, 2019 07:00 am ET
Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a second open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. Patients in the trial will be randomized to receive either 12 mg twice-daily or 24 mg on
May 14, 2019 07:00 am ET
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences:
May 02, 2019 07:00 am ET
Concert Pharmaceuticals Reports First Quarter 2019 Financial Results
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2019.
Apr 29, 2019 07:00 am ET
Concert Pharmaceuticals Names Jesper Høiland to its Board of Directors
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced today that Jesper Høiland has been appointed to its Board of Directors and will serve as a member of its Compensation Committee, effective immediately.
Apr 25, 2019 07:00 am ET
Concert Pharmaceuticals to Report First Quarter 2019 Financial Results on May 2, 2019
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2019 financial results on Thursday, May 2, 2019, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss first quarter financial results and provide
Apr 12, 2019 07:45 am ET
Report: Exploring Fundamental Drivers Behind Visteon, Senseonics, Concert Pharmaceuticals, Cincinnati Bell, Protagonist Therapeutics, and THL Credit — New Horizons, Emerging Trends, and Upcoming Devel
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Visteon Corporation (NASDAQ:VC), Senseonics Holdings, Inc. (NYSE:SENS),...
Apr 11, 2019 07:00 am ET
Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata will be presented in a poster presentation and a sponsored lecture at the 11th Annual World Congress for Hair Research (WCHR) being held April 24-27, 2019 in Sit
Apr 10, 2019 06:30 am ET
Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an additional trial in the Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. The Phase 1 multiple-ascending dose trial will evaluate th
Apr 08, 2019 02:45 pm ET
Concert Pharmaceuticals Announces Decision from Patent Trial and Appeal Board in IPR Proceeding
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a final written decision in connection with the inter partes review (IPR) of U.S. Patent No. 9,249,149 (the ‘149 patent). While PTAB found that the clai
Mar 12, 2019 07:00 am ET
Concert Pharmaceuticals to Present at Upcoming Oppenheimer Healthcare Conference
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019 at 1:00 p.m. ET in New York, NY.
Mar 06, 2019 07:00 am ET
Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. The trial is intended to inform the optimal dosing regimen for CTP-543 for future clinical tri
Mar 01, 2019 07:00 am ET
Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Academy of Dermatology Annual Meeting
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim results from its Phase 2 clinical trial evaluating its product candidate CTP-543 in patients with moderate-to-severe alopecia areata will be presented in an oral presentation during the late-breaking clinical trials session at the Ameri
Feb 28, 2019 07:00 am ET
Concert Pharmaceuticals Reports Year Ended 2018 Financial Results and Provides Update on Clinical Programs
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the year ended December 31, 2018, as well as provided an update on its product pipeline and corporate activities.
Feb 21, 2019 07:00 am ET
Concert Pharmaceuticals to Report Full Year 2018 Results on February 28, 2019
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2018, on Thursday, February 28, 2019, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss 2018 financial res
Feb 12, 2019 08:00 am ET
Analysis: Positioning to Benefit within Masco, Ascena Retail Group, Leidos, NetScout, MYR Group, and Concert Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Masco Corporation (NYSE:MAS), Ascena Retail Group, Inc. (NASDAQ:ASNA),...
Feb 11, 2019 07:00 am ET
Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata has been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 1 - 5, 201
Jan 24, 2019 07:00 am ET
Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated the second Phase 1 clinical trial with CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. The Phase 1 single-ascending dose trial will evaluate the safety, tolerab
Jan 22, 2019 07:00 am ET
Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of the final cohort evaluating 12 mg twice daily of CTP-543 in its Phase 2a trial for the treatment of moderate-to-severe alopecia areata. The trial previously enrolled patients to receive 4 mg and 8 mg twice da
Dec 17, 2018 07:00 am ET
Concert Pharmaceuticals Initiates Phase 1 Clinical Program of CTP-692 for the Treatment of Schizophrenia
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated its Phase 1 clinical program for CTP-692, which is being developed as a novel adjunctive treatment for schizophrenia, a devastating, chronic illness with significant unmet need. CTP-692 is a deuterated form of D-serine, an endo
Nov 12, 2018 08:45 am ET
Report: Exploring Fundamental Drivers Behind Sterling Construction, Tredegar, j2 Global, Medical Transcription Billing, Concert Pharmaceuticals, and Senseonics — New Horizons, Emerging Trends, and Upc
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Sterling Construction Company Inc (NASDAQ:STRL), Tredegar Corporation...
Nov 12, 2018 07:00 am ET
Concert Pharmaceuticals Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced interim topline results from the first two cohorts of its Phase 2a trial evaluating its investigational treatment CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resu
Nov 07, 2018 07:00 am ET
Concert Pharmaceuticals to Participate at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences:
Nov 05, 2018 04:01 pm ET
Concert Pharmaceuticals Presents Preclinical Data on CTP-692, a Novel Drug Candidate for Schizophrenia, Supporting Potential to Improve Safety Profile of D-Serine
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented preclinical results that support the potential of CTP-692, the Company’s novel drug candidate for schizophrenia, to improve the safety profile of D-serine. CTP-692 is a deuterated form of D-serine, an endogenous co-agonist of the N-methyl-D-aspartate (N
Nov 01, 2018 07:00 am ET
Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Company Update
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2018.
Oct 25, 2018 07:00 am ET
Concert Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 1, 2018
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2018 financial results on Thursday, November 1, 2018, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss third quarter financial results and pro
Oct 12, 2018 09:15 am ET
Detailed Research: Economic Perspectives on Graco, Immunomedics, Concert Pharmaceuticals, Macquarie Infrastructure, Systemax, and Service Corporation International — What Drives Growth in Today's Comp
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Graco Inc. (NYSE:GGG), Immunomedics, Inc. (NASDAQ:IMMU), Concert...
Sep 26, 2018 07:00 am ET
Concert Pharmaceuticals Amends Protocol of Phase 2a Trial to Evaluate 12 mg Twice-Daily Dose Cohort of CTP-543 for the Treatment of Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will include an additional cohort of patients in the Phase 2a trial evaluating CTP-543. The protocol amendment provides for additional patients to be enrolled in the trial in order to evaluate a 12 mg dose of CTP-543 or placebo twice daily for 2
Aug 29, 2018 07:00 am ET
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences:
Aug 07, 2018 08:30 am ET
Consolidated Research: 2018 Summary Expectations for Independent Bank Group, Concert Pharmaceuticals, Bank of Marin, Eclipse Resources, MKS Instruments, and Container Store — Fundamental Analysis, Key
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Independent Bank Group, Inc (NASDAQ:IBTX), Concert Pharmaceuticals, Inc....
Aug 02, 2018 07:00 am ET
Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Company Update
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2018.
Jul 26, 2018 07:00 am ET
Concert Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2018 financial results on Thursday, August 2, 2018, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss second quarter financial results and pro
May 03, 2018 07:00 am ET
Concert Pharmaceuticals Reports First Quarter 2018 Financial Results
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2018.
Apr 26, 2018 07:00 am ET
Concert Pharmaceuticals to Report First Quarter 2018 Financial Results on May 3, 2018, and Present at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2018 financial results on Thursday, May 3, 2018, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss first quarter financial results and provide
Apr 25, 2018 07:00 am ET
Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata. The Company expects to report topline data from the 4 mg and 8 mg cohorts of the Phase 2a trial in the fourth quar
Apr 23, 2018 07:35 am ET
Research Report Identifies Signature Bank, Concert Pharmaceuticals, Easterly Government Properties, Hilltop, Columbia Banking System, and New Jersey Resources with Renewed Outlook — Fundamental Analys
NEW YORK, April 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Signature Bank (NASDAQ:SBNY), Concert Pharmaceuticals, Inc....
Mar 06, 2018 07:00 am ET
Concert Pharmaceuticals Present at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences:
Mar 01, 2018 07:00 am ET
Concert Pharmaceuticals Reports Year Ended 2017 Financial Results
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the year ended December 31, 2017, as well as provided an update on its product pipeline and corporate activities.
Feb 28, 2018 04:05 pm ET
Concert Pharmaceuticals Announces Advancement of Novel Drug Candidate in Schizophrenia
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the next development candidate in its product pipeline with the selection of CTP-692, a novel drug for adjunctive treatment of schizophrenia, a devastating, chronic illness with significant unmet need. CTP-692 is a deuterated form of D-serine, an endoge
Feb 22, 2018 08:10 am ET
Report: Developing Opportunities within M.D.C., Concert Pharmaceuticals, WellCare Health Plans, Dextera Surgical, Continental Resources, and Western Union — Future Expectations, Projections Moving int
NEW YORK, Feb. 22, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of M.D.C. Holdings, Inc. (NYSE:MDC), Concert Pharmaceuticals,...
Feb 21, 2018 07:00 am ET
Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2017, on Thursday, March 1, 2018, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss 2017 financial results
Feb 12, 2018 07:00 am ET
Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated enrollment of the second cohort of its Phase 2a clinical trial evaluating CTP-543. Concert is developing CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hai
Jan 12, 2018 07:05 am ET
FDA Grants Fast Track Designation to Concert Pharmaceuticals’ CTP-543 for the Treatment of Alopecia Areata
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543, a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system att
Jan 12, 2018 07:00 am ET
Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did Not Institute PGR Proceeding
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has decided not to grant the Company’s Post Grant Review (PGR) petition challenging the validity of U.S. Patent No. 9,662,335 (referred to as the ’335 patent) assig
Dec 18, 2017 07:00 am ET
Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the appointment of Marc Becker as Chief Financial Officer, effective January 4, 2018. Mr. Becker is a seasoned financial executive with more than 15 years of experience in the biotechnology industry.
Dec 13, 2017 07:00 am ET
Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 18, 2017.
Dec 05, 2017 09:15 am ET
Recent Analysis Shows Dextera Surgical, Continental Resources, Western Union, M.D.C., Concert Pharmaceuticals, and WellCare Health Plans Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Dextera Surgical Inc. (NASDAQ:DXTR), Continental...
Nov 09, 2017 07:00 am ET
Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017.
Nov 06, 2017 07:00 am ET
Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed enrollment of the first cohort of its Phase 2a trial evaluating CTP-543. Concert is developing CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicle
Nov 02, 2017 07:00 am ET
Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at Upcoming Investor Conferences
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2017 financial results on Thursday, November 9, 2017, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. EST to discuss third quarter financial results and pr
Oct 19, 2017 01:00 pm ET
Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trials and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has denied Incyte’s petition to institute inter partes review (IPR) of U.S. Patent No. 9,249,149 (the ‘149 patent). The denial of Incyte’s IPR petition upholds the
Oct 24, 2016 10:00 am ET

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.